此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

通过抑制因子XI减少成年外周动脉疾病患者的不良血管结局 (ROXI-PALISADE)

2026年11月3日 更新者:Regeneron Pharmaceuticals

一项评估REGN7508和REGN9933(靶向XI因子单克隆抗体)在近期因症状性外周动脉疾病接受下肢血运重建术患者中的疗效和安全性的3期、多中心、随机研究主方案(ROXI-PALISADE)

This study is researching 2 different experimental drugs called REGN7508 and REGN9933. The study is focused on people who have Peripheral Artery Disease (PAD), which means that the blood vessels in their arms and legs have become too narrow. People with PAD have a higher risk of getting blood clots after procedures like Lower Extremity Revascularization (LER), a procedure to improve blood flow in the legs and feet.

The aim of this study is to see how well REGN7508 and REGN9933 prevent life-threatening blood clots in participants with PAD who have recently had LER. The effects of REGN7508 and REGN9933, individually, will also be compared to rivaroxaban and a placebo.

The study is looking at several other research questions, including:

  • What side effects might happen from taking the study drugs and how do they compare to the side effects of rivaroxaban
  • How much study drug is in the blood at different times
  • Whether the body makes antibodies against the study drugs (which could make the drugs less effective or could lead to side effects)
  • If the study drugs affect the ability of the blood to clot normally

研究概览

研究类型

介入性

注册 (估计的)

7050

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Alabama
      • Alexander City、Alabama、美国、35010
        • 招聘中
        • Lake Martin Medical and Vascular Center
      • Alexander City、Alabama、美国、35010
        • 招聘中
        • Advanced Cardiovascular
    • Arizona
      • Avondale、Arizona、美国、85392
        • 招聘中
        • Axsendo Clinical Research, Integrated Medical Services
    • Arkansas
      • Little Rock、Arkansas、美国、72205
        • 招聘中
        • Applied Research Center of Arkansas
    • California
      • Los Angeles、California、美国、90010
        • 招聘中
        • Angel City Research, Inc.
      • Oxnard、California、美国、93036
        • 招聘中
        • Pacific Cardiovascular and Vein Institute
      • West Hills、California、美国、91307
        • 招聘中
        • Interventional Cardiology Medical Group
    • Florida
      • Crystal River、Florida、美国、34429
        • 招聘中
        • Nature Coast Clinical Research - Cardiology
      • Jacksonville、Florida、美国、32209
        • 招聘中
        • University of Florida (UF) Health Jacksonville Clinical Center
      • Miami Lakes、Florida、美国、33014
        • 招聘中
        • Inpatient Research Clinic LLC
      • Panama City、Florida、美国、32405
        • 招聘中
        • Cardiovascular Institute of Northwest Florida, Main Office
      • Tampa、Florida、美国、33614
        • 招聘中
        • Tampa Cardiovascular Interventions and Research
    • Indiana
      • Fort Wayne、Indiana、美国、46804
        • 招聘中
        • Lutheran Medical Group LLC dba Lutheran Health Physicians
      • Hammond、Indiana、美国、46324
        • 招聘中
        • ASHA Clinical Research Munster, LLC
      • Munster、Indiana、美国、46321
        • 招聘中
        • Profound Research, Powers Health Medical Group
    • Louisiana
      • Shreveport、Louisiana、美国、71103
        • 招聘中
        • Cardiovascular Solutions
    • Mississippi
      • Petal、Mississippi、美国、39465
        • 招聘中
        • Rovia Clinical Research - Hattiesburg Clinic
    • New Jersey
      • Flemington、New Jersey、美国、08822
        • 招聘中
        • Advanced Heart and Vascular Institute of Hunterdon
    • New York
      • Valhalla、New York、美国、10595
        • 招聘中
        • Westchester Medical Center
    • North Carolina
      • Charlotte、North Carolina、美国、28207
        • 招聘中
        • Mecklenburg Heart Specialists Vascular Institute and Vein Center
      • Mooresville、North Carolina、美国、28117
        • 招聘中
        • Accellacare of Piedmont, Piedmont Healthcare
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73102
        • 招聘中
        • Hightower Clinical
    • South Dakota
      • Rapid City、South Dakota、美国、57701
        • 招聘中
        • Monument Health Clinical Research
    • Tennessee
      • Jackson、Tennessee、美国、38301
        • 招聘中
        • Apex Research Foundation, LLC
      • Knoxville、Tennessee、美国、37934
        • 招聘中
        • Tennova TCMC
      • Tullahoma、Tennessee、美国、37388
        • 招聘中
        • Vanderbilt Heart and Vascular Tullahoma, Cardiology and Vascular Associates
    • Texas
      • Amarillo、Texas、美国、79106
        • 招聘中
        • PharmaTex Research
      • Cypress、Texas、美国、77429
        • 招聘中
        • Vital Heart and Vein
      • DeSoto、Texas、美国、75115
        • 招聘中
        • Epic Medical Research
      • Plano、Texas、美国、75093
        • 招聘中
        • Epic Medical Research-Plano
      • Doncaster、英国、DN2 5LT
        • 招聘中
        • Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust
      • London、英国、W6 8RF
        • 招聘中
        • Charing Cross Hospital

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria:

  1. Successful LER distal to the external iliac artery for ischemia due to atherosclerotic disease within 10 days prior to randomization as described in the protocol

  2. At least 1 of the following enrichment factors for major thrombotic vascular events:

    1. Bypass with prosthetic graft
    2. Endovascular treatment with stenting
    3. Target lesion length >15 cm
    4. History of LER or amputation for PAD prior to qualifying LER
    5. Type 2 diabetes mellitus requiring pharmacologic treatment
    6. Comorbid symptomatic coronary artery disease as described in the protocol
    7. Chronic kidney disease as described in the protocol
    8. Age ≥75 years

Key Exclusion Criteria:

  1. Has any active clinical condition requiring chronic therapeutic anticoagulation after the index revascularization including known triple positive antiphospholipid syndrome
  2. Has known bleeding diathesis, platelet count <50,000/mm^3 or history of non-traumatic intracerebral hemorrhage, known cerebral amyloid angiopathy, or known unrepaired cerebrovascular malformations
  3. Has recent coronary revascularization as described in the protocol
  4. For Cohort 2 only: Has estimated Glomerular Filtration Rate (eGFR) <15 mL/min/1.73m^2 within 14 days prior to randomization or on dialysis or expected to be started on dialysis within the next 12 weeks starting from randomization
  5. Has any other condition or therapy which would make the participant unsuitable for this study or not allow participation for the full planned study period
  6. Has allergy, hypersensitivity, or other contraindication to REGN7508, REGN9933, or rivaroxaban (Cohort 2 only) or their excipients

Note: Other Protocol Defined Inclusion/ Exclusion Criteria Apply

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:队列 1

Administered per the protocol

Administered per the protocol

其他名称:
  • cenvacibart

Administered per the protocol

其他名称:
  • amrecibart
实验性的:队列 2

Administered per the protocol

其他名称:
  • cenvacibart

Administered per the protocol

其他名称:
  • amrecibart

Administered per the protocol

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Time-to-first occurrence of a major thrombotic vascular event, consisting of Acute Limb Ischemia (ALI), major amputation (above the ankle) of vascular etiology, Myocardial Infarction (MI), ischemic stroke, or Cardiovascular (CV) death
大体时间:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of International Society of Thrombosis and Hemostasis (ISTH) major or Clinically Relevant Non-major (CRNM) bleeding
大体时间:Approximately up to 42 months

Cohort 1 and 2

Approximately up to 42 months

次要结果测量

结果测量
措施说明
大体时间
Total (first and subsequent) occurrences of major thrombotic vascular events, consisting of ALI, major amputation (above the ankle) of vascular etiology, MI, ischemic stroke, or CV death
大体时间:Approximately up to 42 months

Cohort 1 and 2

Approximately up to 42 months
Time-to-first occurrence of an expanded thrombotic vascular event, consisting of ALI, major amputation (above the ankle) of vascular etiology, MI, ischemic stroke, CV death, unplanned index limb revascularization, or Venous Thromboembolism (VTE)
大体时间:Approximately up to 42 months

Cohort 1 and 2

Approximately up to 42 months
Time-to-first occurrence of ALI, major amputation (above the ankle) of vascular etiology, MI, ischemic stroke or coronary death
大体时间:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of vascular hospitalization for a coronary cerebrovascular, or peripheral event of thrombotic nature
大体时间:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of ALI, major amputation of vascular etiology, MI, ischemic stroke, or all-cause mortality
大体时间:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of unplanned index limb revascularization for ischemia
大体时间:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of VTE
大体时间:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-all-cause mortality
大体时间:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of Major Adverse Limb Event (MALE)
大体时间:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of Major Adverse Cardiovascular Event (MACE)
大体时间:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of a major thrombotic vascular event or ISTH fatal/critical organ bleeding (net clinical benefit)
大体时间:Approximately up to 42 months

Cohort 1

Approximately up to 42 months
Time-to-first occurrence of Thrombolysis in Myocardial Infarction (TIMI) major bleeding
大体时间:Approximately up to 42 months

Cohort 1 and 2

Approximately up to 42 months
Occurrence of Treatment-Emergent Adverse Event (TEAEs)
大体时间:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Severity of TEAEs
大体时间:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Occurrence of Anti-Drug Antibody (ADA) to REGN7508 over time
大体时间:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Magnitude of ADA to REGN7508 over time
大体时间:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Occurrence of ADA to REGN9933 over time
大体时间:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Magnitude of ADA to REGN9933 over time
大体时间:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Concentrations of REGN7508 over time
大体时间:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Concentrations of REGN9933 over time
大体时间:Approximately up to 45 months

Cohort 1 and 2

Approximately up to 45 months
Change from baseline in activated Partial Thromboplastin Time (aPTT) over time
大体时间:Approximately up to week 9

Cohort 1 and 2

Approximately up to week 9
Change from baseline in Prothrombin Time (PT)/International Normalization Ratio (INR) over time
大体时间:Approximately up to week 9

Cohort 1 and 2

Approximately up to week 9
Total (first and subsequent) occurrences of expanded thrombotic vascular events
大体时间:Approximately up to 42 months

Cohort 2

Approximately up to 42 months
Time-to-first occurrence of a major thrombotic vascular event
大体时间:Approximately up to 42 months

Cohort 2

Approximately up to 42 months
Total (first and subsequent) occurrences of ALI, major amputation (above the ankle) of vascular etiology, MI, all-cause stroke, or CV death
大体时间:Approximately up to 42 months

Cohort 2

Approximately up to 42 months
Total (first and subsequent) occurrences of ALI, major amputation (above the ankle) of vascular etiology, MI, all-cause stroke, CV death, unplanned index limb revascularization, or VTE
大体时间:Approximately up to 42 months

Cohort 2

Approximately up to 42 months

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 研究主任:Clinical Trial Management、Regeneron Pharmaceuticals

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年7月10日

初级完成 (估计的)

2029年8月18日

研究完成 (估计的)

2029年11月16日

研究注册日期

首次提交

2026年1月2日

首先提交符合 QC 标准的

2026年1月2日

首次发布 (实际的)

2026年1月6日

研究记录更新

最后更新发布 (实际的)

2026年11月5日

上次提交的符合 QC 标准的更新

2026年11月3日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.

IPD 共享时间框架

When Regeneron has:

  • received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
  • made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
  • the legal authority to share the data, and
  • ensured the ability to protect participant privacy

IPD 共享访问标准

Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

IPD 共享支持信息类型

  • 研究方案
  • 树液
  • 国际碳纤维联合会
  • 分析代码
  • 企业社会责任

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅